yingweiwo

Fospropofol Disodium

Alias: GPI-15715 GPI15715 lusedraFospropofol Disodium fospropofolGPI 15715 Aquavan Lusedra UNII-30868AY0IF
Cat No.:V6054 Purity: =99.36%
Fospropofol Disodium is discontinued because it is a DEA controlled substance.
Fospropofol Disodium
Fospropofol Disodium Chemical Structure CAS No.: 258516-87-9
Product category: New1
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
5mg

Other Forms of Fospropofol Disodium:

  • Fospropofol
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: =99.36%

Product Description

Fospropofol Disodium is discontinued because it is a DEA controlled substance. It is a potent and short acting hypnotic/sedative/anesthetic agent. Fospropofol disodium for injection (FospropofolFD) is a prodrug that is metabolized into propofol to produce a general anesthesia effect when administered intravenously.

Biological Activity I Assay Protocols (From Reference)
Targets
GABAA receptor
ln Vitro
Fospropofol, a phosphate ester ater soluble prodrug of propofol has been found to be safe and effective alternative to propofol and midazolam for use in endoscopic and other procedures. The unique pharmacology of fospropofol provides scope for expansion to introduce new drug options for sedation.Fospropofol gets converted to propofol by endothelial alkaline phosphatases5 Propofol is a agonist at GABAA receptor .It binds to a specific site on the a and 11 subunits of the receptor complex, but not to the GABA binding site. Activation of the GABAA receptor results in increased Cl-conductance and hyperpolarization, thus inhibiting the postsynaptic neuron. It also inhibits the excitatory NMDA glutamate receptors thus decreasing Ca++ entry resulting in postsynaptic inhibition. Above mechanisms results in sedation.[1]
ln Vivo
A total of 347 (96.3%) and 175 (97.2%) patients in the intervention and control groups, respectively, completed the study. The success rate for the primary outcome was 97.7% for both study drugs. The most frequent AEs in the intervention group were abnormal feeling (62.0%), blood pressure reduction (13.5%), and injection site pain (13.3%). No AEs related to consciousness and mental and cognitive functions or serious adverse events were reported.[2]
Toxicity/Toxicokinetics
Effects During Pregnancy and Lactation
◉ Overview of Lactation Use
Currently, there is no information regarding the clinical use of fosprofen during lactation. However, fosprofen is rapidly metabolized into propofol in the body. The amount of propofol in breast milk is extremely low and is not expected to be absorbed by the infant. Although some expert panels recommend suspending breastfeeding for a period of time after propofol administration (specific duration undetermined), most experts recommend resuming breastfeeding once the mother has recovered sufficiently from general anesthesia to breastfeed, without discarding the milk. When multiple anesthetics are used during surgery, the recommendations for the most likely adverse reaction should be followed. General anesthesia for cesarean section using propofol as a component of labor induction may delay the onset of lactation. One study showed that breastfeeding before induction of general anesthesia reduced the need for propofol and sevoflurane compared to breastfeeding mothers who stopped breastfeeding or non-breastfeeding women. Case reports indicate that breast milk turned green after a breastfeeding mother received propofol.
◉ Effects on Breastfed Infants
Four breastfeeding mothers underwent surgery with propofol as part of general anesthesia. All patients also received intravenous remifentanil and rocuronium bromide, and inhaled xenon as part of anesthesia. The target serum concentration of propofol they received was 6.5 mcg/L for induction of anesthesia, and was discontinued upon initiation of xenon inhalation anesthesia. The surgery lasted 35 to 45 minutes. The infants first breastfed at 1.5 hours, 2.8 hours, 4.6 hours, and 5 hours after extubation. No signs of sedation were observed in any of the infants.
◉ Effects on Lactation and Breast Milk
Five women 6 to 15 weeks postpartum received a single intravenous dose of 2 mg midazolam and 2.5 mg/kg propofol, respectively, before general anesthesia. Postoperatively, these women produced less than half the normal milk production of breastfeeding women. The authors hypothesize that the reduced postoperative milk production may be due to perioperative fluid restriction and loss, as well as stress-induced lactation suppression. A woman underwent emergency laparoscopic surgery, during which propofol, fentanyl, remifentanil, mirtazapine, and aminopyrine were administered. Postoperatively, aminopyrine, pyrithione, aminopyrine, butylscopolamine bromide, and metoclopramide were used. Eight hours postoperatively, her breast milk first turned blue-green, then green. Both propofol and metoclopramide can cause green urine. Thirty hours after the milk color change, propofol was detected in the breast milk, but metoclopramide was not detected. A randomized study compared the effects of cesarean section under general anesthesia, spinal anesthesia, or epidural anesthesia versus normal vaginal delivery on serum prolactin and oxytocin levels and the time to lactation initiation. General anesthesia was induced with propofol 2 mg/kg and rocuronium bromide 0.6 mg/kg, followed by sevoflurane and rocuronium bromide 0.15 mg/kg as needed. Fentanyl 1 to 1.5 mcg/kg was administered postpartum. Patients in the general anesthesia group (n = 21) had higher postoperative prolactin levels and a longer mean time to lactation initiation (25 hours) than other groups (10.8 to 11.8 hours). Postpartum oxytocin levels were higher in the non-pharmacological vaginal delivery group than in the general anesthesia and spinal anesthesia groups. A randomized, double-blind study compared the effects of intravenous propofol 0.25 mg/kg, ketamine 0.25 mg/kg, ketamine 25 mg plus propofol 25 mg, and placebo saline on postpartum analgesia after cesarean section. A single dose was administered immediately after umbilical cord ligation. The time to first breastfeeding was 58 minutes in the placebo group, 42.6 minutes in the propofol group, and 25.8 minutes in the propofol plus ketamine group. The time to first breastfeeding was significantly shorter in the combination therapy group than in the other groups. A retrospective study compared women undergoing elective cesarean sections at a hospital in Turkey, including women receiving bupivacaine spinal anesthesia (n = 170) and women receiving general anesthesia (n = 78). General anesthesia was induced with propofol, maintained with sevoflurane, and administered postpartum fentanyl. There was no difference in breastfeeding rates between the two groups at 1 hour and 24 hours postpartum. However, at 6 months postpartum, 67% of women in the general anesthesia group were still breastfeeding, compared to 81% in the spinal anesthesia group—a statistically significant difference. A woman who breastfed 6 to 8 times daily and was nursing an 8-month-old infant was admitted for an appendectomy. During the surgery, she received cefazolin, granisetron, ketorolac, rocuronium, succinylcholine, and sufentanil. The patient also received two intravenous boluses of 150 mg propofol, followed shortly by an intravenous bolus of 50 mg propofol. Post-operatively, she took acetaminophen, cefazolin, ibuprofen, and pantoprazole, and oxycodone and dimenhydrinate as needed. Twenty-two hours post-operatively, the mother expressed her first breast milk, which was light green. Analysis of the green milk using an unverified detection method did not detect propofol. On the fourth day post-operatively, when she resumed breastfeeding, the green color gradually faded and disappeared. The authors believe the green color was likely caused by propofol or its metabolites. A pregnant woman underwent an emergency cesarean section at 24 weeks of gestation. During the procedure, she received 200 mg of propofol and cefazolin and acetaminophen post-delivery. Twelve hours post-operatively, the mother's first expressed breast milk was dark green. Thirty hours post-operatively, the milk turned light green and returned to its normal color after 48 hours.
References
[1]. J Anaesthesiol Clin Pharmacol. 2011 Jan-Mar; 27(1): 79–83.
[2]. Front Pharmacol. 2021; 12: 687894.
[3]. A double-blind, randomized, multicenter, dose-ranging study to evaluate the safety and efficacy of fospropofol disodium as an intravenous sedative for colonoscopy in high-risk populations. Am J Ther. 2013 Mar-Apr;20(2):163-71.
Additional Infomation
See also: propofol (with the active moiety); phosphoprothodol (its salt form).
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C13H19NA2O5P
Molecular Weight
332.24
Exact Mass
332.076
Elemental Analysis
C, 47.00 H, 5.76 Na, 13.84 O, 24.08 P, 9.32
CAS #
258516-87-9
Related CAS #
258516-87-9(Disodium);258516-89-1(Free acid);258516-87-9
PubChem CID
3038497
Appearance
Typically exists as solid at room temperature
Boiling Point
441.5ºC at 760mmHg
Flash Point
220.8ºC
Vapour Pressure
1.43E-08mmHg at 25°C
LogP
4.255
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
5
Rotatable Bond Count
5
Heavy Atom Count
21
Complexity
285
Defined Atom Stereocenter Count
0
SMILES
[Na+].[Na+].O=P(OCOC1C(C(C)C)=CC=CC=1C(C)C)([O-])[O-]
InChi Key
LWYLQNWMSGFCOZ-UHFFFAOYSA-L
InChi Code
InChI=1S/C13H21O5P.2Na/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16;;/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16);;/q;2*+1/p-2
Chemical Name
[2,6-di(propan-2-yl)phenoxy]methyl phosphatedisodium
Synonyms
GPI-15715 GPI15715 lusedraFospropofol Disodium fospropofolGPI 15715 Aquavan Lusedra UNII-30868AY0IF
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.0099 mL 15.0494 mL 30.0987 mL
5 mM 0.6020 mL 3.0099 mL 6.0197 mL
10 mM 0.3010 mL 1.5049 mL 3.0099 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Efficacy and Safety of Fospropofol Disodium Versus Propofol for Sedation in Mechanically Ventilated ICU Patients
CTID: NCT05491278
Phase: Phase 2
Status: Completed
Date: 2023-09-21
Efficacy and Safety of Fospropofol Disodium Versus Propofol for Deep Sedation in Critically Ill Patients
CTID: NCT05870514
Phase: Phase 2
Status: Recruiting
Date: 2023-07-05
A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy
CTID: NCT00209599
Phase: Phase 2
Status: Terminated
Date: 2023-06-18
A Study of AQUAVAN® Injection for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy
CTID: NCT00209586
Phase: Phase 3
Status: Terminated
Date: 2023-06-15
A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion
CTID: NCT01308541
Phase: Phase 1
Status: Completed
Date: 2015-11-03
Contact Us